Navigation Links
DURECT to Present at the BMO Capital Markets Healthcare Conference
Date:7/28/2009

CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5 at 4:00 pm Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City. A webcast of the presentation will be accessible at: http://www.bmocm.com/conferences/2009healthcare/webcast/.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
2. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
3. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
4. DURECT to Participate in Cowen and Company Healthcare Conference
5. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation to Participate in Upcoming Healthcare Conferences
9. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
10. DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
11. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata ... and boosting quality. , It’s known as the “CY2016 Annual FDA Medical Device ...
(Date:7/20/2017)... SANTA CLARA, CA (PRWEB) , ... July 20, ... ... some form of travel protection services since 2014, top travel insurance solution company ... agents the tools to sell all major international travel insurance products online, under ...
(Date:7/20/2017)... ... July 19, 2017 , ... At Creekwood Dental Arts, Drs. ... joint (TMJ) treatment and dental implants in Waco, TX, using the latest ... the T-Scan™ by Tekscan®, they can capture details in the oral cavity for accurate ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July 7th ... to, or worsen, varicose veins in some patients, according to medical experts. Washington ... not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while shaving ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful carpal tunnel ... syndrome affects more than 8 million people a year. Women suffer ... common methods of treating CTS are painful surgery, the use of ... ... is a clear patch worn on the palm of the hand. ...
(Date:7/11/2017)... Research Corp., also known as ,The Epigenetics Company, announced today the release ... manner using the myDNAge ™ test. Based on Horvath,s Clock, so ... and biostatistics at the David Geffen School of Medicine at UCLA ... DNAge ™ technology is used to analyze DNA methylation patterns of ... ...
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
Breaking Medicine Technology: